Concord Wealth Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Concord Wealth Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21	Closed	-$3K	–	1289
2022 Q2	$3K	Hold	21	–	–	﹤0.01%	982
2022 Q1	$2K	Hold	21	–	–	﹤0.01%	1164
2021 Q4	$3K	Hold	21	–	–	﹤0.01%	1092
2021 Q3	$3K	Hold	21	–	–	﹤0.01%	727
2021 Q2	$2K	Hold	21	–	–	﹤0.01%	936
2021 Q1	$1K	Hold	21	–	–	﹤0.01%	991
2020 Q4	$2K	Buy	+21	New	+$1.78K	﹤0.01%	589

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Concord Wealth Partners's BHVN Position: Q3 2022 in Review

Concord Wealth Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 21 shares — an estimated $3K sold.

Concord Wealth Partners first reported a position in BHVN in Q4 2020 and held it in 7 quarters. The position peaked at $3K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Concord Wealth Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Concord Wealth Partners sold 21 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $3K.
Concord Wealth Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 7 quarters.
Concord Wealth Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3K in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Concord Wealth Partners's 13F filing for Q3 2022, filed 10 Nov 2022.